Disc Medicine Stock
Disc Medicine, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John D. Quisel
- Employees
- 165
- Market cap
- $2.2 B
- IPO
- 12/08/2020
Based in Watertown, USA, Disc Medicine, Inc. is a clinical-stage biotechnology company operating within the healthcare sector. The company's core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. It is…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Disc Medicine stock: price history
1D
+0.3%
1W
-8.4%
1M
-17.1%
6M
-20.8%
YTD
-28.4%
1Y
-23.6%
2Y
+18.4%
5Y
+52.8%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~8% stronger price swings than usual
Ask the agents about Disc Medicine
Analyst assessment of Disc Medicine
PRICE TARGET LOW
US$86.00
CONSENSUS
US$106.00
MEDIAN
US$105.00
PRICE TARGET HIGH
US$128.00
1
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 16/09/2026
Disc Medicine stock metrics
P/E
-8.61
P/B
3.41
EV/EBITDA
-8.87
RETURN ON EQUITY
-9.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.3%
FLOAT SHARES
28,153,824
AVG. DAILY VOLUME (30D)
617,825
Insider transactions (SEC)
Quisel John D
Bitterman Kevin
Bitterman Kevin
Bitterman Kevin
Bitterman Kevin
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.3%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Disc Medicine stock
What does Disc Medicine do?
Disc Medicine, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John D. Quisel, the company employs around 165 people.
The IPO was on 12/08/2020; the stock trades on NASDAQ under the ticker IRON.
What do analysts say about Disc Medicine stock?
11 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$106.00, ranging from US$86.00 to US$128.00, with a median of US$105.00.
This is an external assessment, not a statement by Market Jury.
When does Disc Medicine report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Disc Medicine pay a dividend?
No, Disc Medicine currently does not pay a dividend.
Which stocks are comparable to Disc Medicine?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Disc Medicine stock analyzed?
Clicking "Analyze stock" lets five strategies assess Disc Medicine against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.